Search

everythinglearnresearchcommunity

for

Search:↓

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

Male cells need DHT to respond to testosterone, while female cells do not.

The study created a new method to test drugs that affect hormone processing in skin.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

New compounds may help treat prostate cancer by reducing cell growth.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.

MK-386 lowers DHT in blood and skin but not in semen.

Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.

New compounds show promise as nonsteroidal treatments for hair loss.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Human bone cells mainly produce a type 1 enzyme that may help regulate bone health.

New chemical compounds were made that effectively block an enzyme linked to prostate growth.

The main enzyme found in pubic skin that could be targeted to treat excessive hair growth is 5 alpha-R2.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Male yak hair growth is influenced by DHT synthesis, which is promoted by 5α-red1 and AR during growth phases, while E2 may inhibit growth through ERα.

Testosterone and dihydrotestosterone treatments can help with penile growth in males with 5α-reductase type 2 deficiency, with dihydrotestosterone being more effective in infancy.

The enzyme 5α-reductase type 1 is important for blood vessel development and fertility in the uterus.

The enzyme 5α-reductase is important for proper blood vessel development during the fertility-related transformation of the uterus lining.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

Key enzymes control androgen levels, affecting hormone activity and potential treatments.

Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

In 2005, men used finasteride mainly to treat an enlarged prostate.

5AR inhibitors like finasteride and dutasteride improve hair growth and slow hair loss in male pattern baldness.

A new plant extract from Avicennia marina could potentially be used to treat common hair loss.

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.

Androgens may influence bladder cancer progression by affecting cellular behavior.